Key Transaction Details

  • Target Company: Panacea Biotec Limited (NSE Symbol: PANACEABIO, BSE Scrip Code: 531349)
  • Acquirer: Rajesh Jain HUF, with Dr. Rajesh Jain as Karta
  • Seller: Dr. Rajesh Jain, Promoter of Panacea Biotec Limited
  • Transaction Type: Inter-se transfer by way of gift without any consideration
  • Number of Shares: 200,000 equity shares
  • Share Price: ₹0 (zero consideration)
  • Date of Acquisition: June 12, 2026

Shareholding Impact

Seller (Dr. Rajesh Jain) Holding Change:

  • Pre-acquisition holding: 30,217,312 shares (13.57% of total share capital)
  • Post-acquisition holding: 30,017,312 shares (13.48% of total share capital)
  • Reduction: 200,000 shares (0.09% dilution)

Acquirer (Rajesh Jain HUF) Holding:

  • Pre-acquisition holding: 0 shares (0%)
  • Post-acquisition holding: 200,000 shares (0.09% of total share capital)

Regulatory Compliance Timeline

  • Notice to Stock Exchanges: Filed at least 4 working days before acquisition (June 5, 2026)
  • SEBI Report Submission: July 8, 2026 (within 21 working days from acquisition)
  • Fee Payment: July 9, 2026 through NEFT (UTR No. 00284938424)
  • Fee Amount: ₹150,000 plus applicable Goods and Services Tax
  • Application Number: 718 dated July 8, 2026 16:03:50

Exemption Conditions Met

  • Regulation: 10(1)(a)(ii) of SEBI Takeover Regulations
  • Share Trading Status: Frequently traded (Yes)
  • 60-day VWAP: ₹387.37 (not applicable for gift transactions)
  • Promoter Status: Both acquirer and seller are named promoters in shareholding pattern
  • Relationship: Acquirer is the HUF of the seller, both belong to Promoters and Promoters Group
  • Immediate Relative Status: No (as per Regulation 2(1)(I))

Additional Compliance

  • Chapter V provisions complied with (Regulation 31(4))
  • Disclosure document filed: Disclosure1.zip
  • Acquirer declaration confirms all exemption conditions under Regulation 10(1)(a)(ii) have been complied with

Financial Impact

  • Transaction executed at zero consideration (gift)
  • No valuation report required as exempt under Regulation 10(1)(a)(ii)
  • No further disclosure obligation under Regulation 29(1) and (2) due to nominal 0.09% holding

Document Verification

  • Filed with National Stock Exchange of India Limited and BSE Limited
  • Copy sent to Company Secretary, Panacea Biotec Limited
  • Declaration signed by Dr. Rajesh Jain as Karta of Rajesh Jain HUF